Bexmarilimab

贝马瑞利单抗

Report date: 2026/03/11 20:02:12

Base Information

Drug NameBexmarilimab
Drug Alias NameClevegenFP-1302FP-1305FP-1304FP-1115
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionStabilin-1 inhibitors
TargetsStabilin-1
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungColonic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsUnited Kingdom +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFaron Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFaron Pharmaceuticals Ltd
Inactive CompaniesUT Health San Antonio
Active IndicationsMyelodysplastic SyndromesSarcomaLeukemia, Myelomonocytic, Chronic +[5] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungColonic NeoplasmsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A